PositiveID (PositiveID) Float Percentage Of Total Shares Outstanding : 32.99% (As of Jun. 06, 2024)

View and export this data going back to 2007. Start your Free Trial

What is PositiveID Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PositiveID's float shares is 3.10 Mil. PositiveID's total shares outstanding is 9.39 Mil. PositiveID's float percentage of total shares outstanding is 32.99%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PositiveID's Insider Ownership is 23.54%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PositiveID's Institutional Ownership is 0.04%.

PositiveID Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

PositiveID's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	3.10	/	9.39
	=	32.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PositiveID (PositiveID) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445

Website

http://www.psidcorp.com

PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.

Executives

Ned L Siegel	director	600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz	director	1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein	director	1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman	other: Former 10% Owner
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K	director	2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105